Genmab enlists another antibody conjugate partner, teaming up with Bolt to develop up to 3 cancer programs
Big Danish biotech Genmab has signed on to a new collaboration, and it’s one both parties hope will tackle a broad swath of cancer indications.
Genmab is partnering with Bolt Biotherapeutics out of Redwood City, CA, to develop up to three new antibody-based conjugates in oncology. In the deal, Genmab is paying Bolt $10 million upfront and investing $15 million in equity, and Bolt is eligible for up to $285 million in milestones per target — a total that could equal $855 million when all is said and done.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.